Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s179. https://doi.org/10.25251/skin.7.supp.179